Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgery

European Journal of Clinical Pharmacology

Volumn 68, Issue 10, 2012, Pages 1403-1410

  Delavenne, Xavier ^a,b   Zufferey, Paul ^a,b   Nguyen, Philippe ^a,c   Rosencher, Nadia ^d   Samama, Charles Marc ^e   Bazzoli, Céline ^f   Mismetti, Patrick ^b   Laporte, Silvy ^a,b,f  

^a University Jean Monnet of Saint Etienne EA3065   (France)

^b UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^c SERVICE DE DERMATOLOGIE   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e HÔTEL DIEU   (France)

^f INSERM   (France)

Author keywords

Fondaparinux; Orthopaedic surgery; Pharmacokinetics; Renal impairment; Simulations

Indexed keywords

FONDAPARINUX;

AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; ORTHOPEDIC SURGERY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; STEADY STATE; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; AREA UNDER CURVE; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FACTOR XA; FEMALE; HUMANS; KIDNEY; MALE; ORTHOPEDIC PROCEDURES; POLYSACCHARIDES; RENAL INSUFFICIENCY; VENOUS THROMBOEMBOLISM;

EID: 84866617072     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1263-0     Document Type: Article

References (17)

1. Arixtra. Fondaparinux sodium. Summary of Product Characteristics. European Medicines Agency. Available at: http://www. ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-In formation/human/000403/WC500027746.pdf. Accessed on December 21, 2011
2. Turpie AG, Bauer KA, Eriksson BI et al (2002) Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162:1833-1840
3. Coresh J, Selvin E, Stevens LA et al (2007) Prevalence of chronic kidney disease in the United States. JAMA 298:2038-2047
4. Samama CM, Ravaud P, Parent F et al (2007) Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study. J Thromb Haemost 5:2360-2367
5. Rosencher N, Vielpeau C, Emmerich J et al (2005) Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. J Thromb Haemost 3:2006-2014
6. Turpie AG, Lensing AWA, Fuji T et al (2009) Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagul Fibrinolysis 20:114-121
7. Mismetti P, Rosencher N, Samama C, et al. (2009) Fondaparinux 1.5 mg in patients with moderate to severe renal impairment undergoing major orthopedic surgery: the PROPICE study. J Thromb Haemost 7(Suppl. 2): abstract OCWE- 002
8. Delavenne X, Zufferey P, Baylot D et al (2010) Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice. Thromb Haemost 104:252-260
9. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
10. Retout S, Duffull S, Mentre F (2001) Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput Methods Programs Biomed 65:141-151
11. Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470
12. Wahlby U, Jonsson EN, Karlsson MO (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28:231-252
13. Mentre F, Escolano S (2006) Prediction discrepancies for the evaluation of nonlinear mixed-effects models. J Pharmacokinet Pharmacodyn 33:345-367
14. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (1998) Guidance for Industry. Pharmacokinetics in patients with impaired renal function - Study design, data analysis, and impact on dosing and labeling
15. Committee for Proprietary Medicinal Products. Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function. The European Agency for the Evaluation of Medicinal Products. London, 23 June 2004; CPMP/EWP/225/02
16. Committee for Proprietary Medicinal Products. Guideline on reporting the results of population pharmacokinetic analyses. The European Agency for the Evaluation of Medicinal Products. London, 28 June 2006; EMEACPMP/EWP/185990/ 2006
17. Donat F, Duret JP, Santoni A et al (2002) The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 41 (Suppl 2):1-9